MAP3K5 and fatty liver disease: Histological scoring by an independent and blinded expert pathologist (Histalim) revealed variably ameliorated hepatic steatosis, ballooning, and lobular inflammation, upon pharmacological inhibition of GPR84 and ASK1, resulting in a significantly reduced NAFLD Activity Score (NAS), overall (Figure 4C).